Calidi Biotherapeutics Granted FDA Fast Track Designation for CLD-201, an Innovative Viral Therapy for Soft Tissue Sarcoma
Wednesday, July 30, 2025
Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company focused on developing targeted treatments using genetic medicine delivery systems, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational therapy CLD-201 (SuperNova). This therapy is designed for patients with soft tissue sarcoma and uses a novel approach involving stem-cell loaded oncolytic viruses.
CLD-201 is an allogeneic therapy made up of adipose-derived mesenchymal stem cells (AD-MSCs) loaded with an oncolytic vaccinia virus. It is being developed for the treatment of advanced solid tumours, including soft tissue sarcoma, triple-negative breast cancer, and head and neck squamous cell carcinoma. The stem-cell delivery method is intended to protect the virus from early immune system clearance, allowing it to replicate within the stem cells. This process is expected to enhance the therapy’s potency and stimulate a stronger immune response, as shown in pre-clinical studies.
The FDA’s Fast Track designation is given to therapies that show potential to address serious conditions and unmet medical needs. This status enables more frequent interaction with the FDA and may offer the opportunity for priority review or accelerated approval during the regulatory process.
CLD-201 received Investigational New Drug (IND) clearance in April 2025. Calidi is preparing for a Phase 1 clinical trial, which will be a first-in-human, open-label, multi-centre study to assess the safety, tolerability, and early signs of efficacy in patients with sarcoma, triple-negative breast cancer, and head and neck cancers.
This development highlights Calidi’s efforts to advance a new class of stem-cell based viral therapies that could offer improved treatment options for patients with difficult-to-treat cancers.
Source: globenewswire.com
